International Clinical Trial: A randomized, double-blind, excipi-controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of ruxolitinib gel (HDM3010) in adult subjects with mild to moderate pruritus nodules

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117276) titled 'A randomized, double-blind, excipi-controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of ruxolitinib gel (HDM3010) in adult subjects with mild to moderate pruritus nodules' on Jan. 21.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Hangzhou First People's Hospital

Condition: prurigo nodularis

Intervention: Group A (1.5% ruxolitinib gel):1.5% ruxolitinib gel, QD, BID Group B (1.5% ruxolitinib gel):1.5% ruxolitinib gel Group C (Excipient ?1.5% ruxolitinib gel QD):Excipient ?1.5% ruxolitinib gel QD

Recruitment Status: Not Recruiting

Phase: 3

Date...